Palatin Technologies Concludes FDA Meeting on Dry Eye Treatment
By Chris Wack Palatin Technologies Inc. said it has completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration for PL9643 for the treatment of dry eye. The biopharmaceutical company said the scope of the…